SEC EDGARSEP 11 min read$XENE

KENNEY CHRISTOPHER JOHN sold $426K of XENE

KENNEY CHRISTOPHER JOHN (Chief Medical Officer) sold 7,068 shares of Xenon Pharmaceuticals Inc. (XENE) at an average of $60.25 ($60.17–$60.98, $0.43M total) across 2 trades on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · KENNEY CHRISTOPHER JOHN

Published Sep 1, 2026, 1:59 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Sep 1, 2026, 2:29 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$XENE

Bearish

medium confidence

Mentioned

$XENE

Relevance

3/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$XENEBearishLow

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

Market read

Small insider sell; limited trading relevance.

What to watch

Potential upcoming clinical data could offset sell pressure.

Relevance 3/10Novelty 3/10Timing: post-market 2026-08-28

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$XENEBearishMedium confidence

Context

Chief Medical Officer sold 7,068 shares for $425,828.99 via a 10b5-1 plan, leaving 2 shares remaining.

Expected impact

Potential modest dip in short term trading.

Evidence & confidence

Sale size is small relative to market cap and executed under a pre-arranged plan, limiting immediate impact.

Market effects

Sector

Minimal effect on biotech sector; typical insider sell.

Regional

Negligible impact on US markets.

Global

None

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not signal lack of confidence.

Key entities

company
Xenon Pharmaceuticals Inc.
Biotech firm listed on NASDAQ under ticker XENE.
person
Kenney Christopher John
Chief Medical Officer of Xenon Pharmaceuticals.

Read at source ← All news

SEP 4

$XENEMedAI 8/10

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

Xenon Pharmaceuticals (XENE) will present data on azetukalner, a potential epilepsy treatment, at the European Epilepsy Congress. The company reported a net loss of $110.7M in Q2 2026, up from $84.7M a year earlier, due to increased R&D and administrative costs. Xenon expects to file for FDA approval of azetukalner in Q3 2026 and is also testing the drug for depression and pain.

yahoo.com2 min

AUG 26

$XENEHighAI 9/10

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Xenon Pharmaceuticals (XENE) will present Phase 3 data for azetukalner, a KV7 channel opener, at the 16th European Epilepsy Congress. The company plans six presentations, including topline X-TOLE2 study results for focal onset seizures and mechanistic characterization of azetukalner's potential additive effects with other antiseizure medications. Xenon aims to highlight azetukalner's differentiated attributes and its potential to enhance seizure control through rational polytherapy.

thestarphoenix.com2 min

AUG 13

$XENEMed

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

Xenon Pharmaceuticals (XENE) reported Q2 2026 results and discussed clinical progress. Cash was $1,245.1M as of June 30, 2026, expected to fund operations into 2029. Q2 net loss was $110.7M ($1.11/share). Management said Azetukalner NDA submission for focal onset seizures is on track for Q3 2026, with Phase 3 programs in major and bipolar depression and pain pipeline updates.

fool.com7 min

AUG 9

$XENEMedAI 8/10

Xenon Pharmaceuticals Q2 Earnings Call Highlights

Xenon Pharmaceuticals reported Q2 revenue changes by region, with Americas up 6% and EMEA up 15% excluding non-recurring license and royalty revenue, while Asia-Pacific fell 19% versus a prior-year China pull-forward. Q2 gross margin rose to 74%. Operating expenses were $132.1M. Cash totaled $552M. Full-year 2026 revenue outlook raised to $610M-$630M.

yahoo.com6 min

AUG 6

$XENEMed

Xenon Pharmaceuticals Inc. (XENE): Results of Operations and Financial Condition

Xenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenon Reports Q2 2026 Financial Results and Provides Business Update • NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA • Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll • Three Phase 3 studies of azetuk

SEC EDGAR 8-K6 min